Harvard Bioscience, Inc. (HBIO) — Financial statements
Income statement, balance sheet, and cash flow for Harvard Bioscience, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 87↓8.1% | 94↓16.1% | 112↓1.0% | 113↓4.7% | 119 | |
| Cost of Revenue | 41↑3.3% | 39↓14.7% | 46↓12.1% | 53↑2.5% | 51 | |
| Gross Profit | 46↓16.2% | 55↓17.1% | 66↑8.6% | 61↓10.1% | 68 | |
| Operating Expenses | ||||||
| R&D Expenses | 9↓15.2% | 10↓11.5% | 12↓4.6% | 12↑14.2% | 11 | |
| General & Administrative Expenses | 18↓17.5% | 21↓5.6% | 23↓7.0% | 24↑0.8% | 24 | |
| Selling & Marketing Expenses | 19↓13.5% | 22↓7.9% | 24↓3.7% | 25↑1.6% | 25 | |
| SG&A Expenses | 37↓15.4% | 44↓6.8% | 47↓5.3% | 50↑1.2% | 49 | |
| Other Expenses | 0.73↓89.4% | 7↑24.3% | 6↓6.2% | 6↑0.8% | 6 | |
| Operating Expenses | 47↓23.7% | 61↓5.0% | 64↓5.3% | 68↑3.3% | 66 | |
| Total Costs & Expenses | 87↓13.1% | 100↓9.1% | 110↓8.2% | 120↑2.9% | 117 | |
| Operating Results | ||||||
| Operating Income | -0.63↑89.9% | -6↓427.9% | 2↑127.3% | -7↓435.6% | 2 | |
| Depreciation & Amortization | 6↓14.9% | 7↓0.2% | 7↓7.6% | 8↓0.6% | 8 | |
| EBITDA | 5↑460.7% | -1↓118.3% | 8↑751.0% | 0.94↓89.5% | 9 | |
| EBIT | -0.63↑92.6% | -8↓917.0% | 1↑115.6% | -7↓573.6% | 1 | |
| Interest & Other Income | ||||||
| Net Interest Income | -5↓53.2% | -3↑10.6% | -4↓40.9% | -3↓65.5% | -2 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 5↑53.2% | 3↓10.6% | 4↑40.9% | 3↑65.5% | 2 | |
| Non-Operating Income | 0.00↓100.0% | 2↑161.4% | 0.86↑384.4% | -0.30↓145.3% | 0.67 | |
| Other Income / Expenses | -57↓940.6% | -5↓22.6% | -4↓98.1% | -2↓1.8% | -2 | |
| Income Before Tax | -57↓392.0% | -12↓356.4% | -3↑72.2% | -9↓6456.4% | -0.14 | |
| Income Tax Expense | -0.69↓192.7% | 0.74↓13.9% | 0.86↑154.9% | 0.34↑127.7% | 0.15 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -57↓357.1% | -12↓263.3% | -3↑64.1% | -10↓3204.2% | -0.29 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -57↓357.1% | -12↓263.3% | -3↑64.1% | -10↓3204.2% | -0.29 | |
| Bottom-Line Net Income | -57↓357.1% | -12↓263.3% | -3↑64.1% | -10↓3204.2% | -0.29 | |
| EPS (Basic) | -12.80↓357.1% | -2.80↓247.8% | -0.81↑65.0% | -2.30↓3139.4% | -0.07 | |
| EPS (Diluted) | -12.80↓357.1% | -2.80↓247.8% | -0.81↑65.0% | -2.30↓3139.4% | -0.07 | |
| Weighted Average Shares | 4↑2.0% | 4↑2.6% | 4↑2.4% | 4↑2.7% | 4 | |
| Weighted Average Diluted Shares | 4↑2.0% | 4↑2.6% | 4↑2.4% | 4↑2.7% | 4 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.